Does ART prevent HIV transmission among MSM?
- 28 November 2012
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in AIDS
- Vol. 26 (18), 2267-2273
- https://doi.org/10.1097/qad.0b013e328355713d
Abstract
Objective: To review the evidence for antiretroviral ‘treatment as prevention’ for HIV transmission among MSM. Methods: We reviewed studies that assess the biological plausibility that virally suppressive antiretroviral therapy (ART) reduces HIV infectiousness via anal intercourse and the epidemiologic evidence of whether ART has played a role in attenuating HIV incidence among MSM. Results: Although ART treatment among MSM is likely to provide some preventive benefit, it is unknown whether it will reduce HIV infectiousness via anal intercourse to the same extent as via penile–vaginal intercourse. Additional research is needed on the pharmacokinetic properties of specific antiretroviral agents in the gastrointestinal tract. Estimates of risk behaviors and the incidence of HIV among MSM before and after the introduction and expansion of ART suggest that the population-level protective benefits of ART may be attenuated by a number of factors, most notably, continuing or increasing frequency of condomless anal intercourse and incidence of other sexually transmitted infections (STIs). Additional studies are needed on the impact of ART on HIV sexual risk behaviors and transmission among MSM outside of developed countries in North America, western Europe, and Australia. Conclusion: The benefits of treatment as prevention for MSM are highly plausible, but not certain. In the face of these unknowns, treatment guidelines for earlier ART initiation should be considered within a combination prevention strategy that includes earlier diagnosis, expanded STI treatment, and structural and behavioral interventions.Keywords
This publication has 66 references indexed in Scilit:
- HIV-1 RNA Rectal Shedding Is Reduced in Men With Low Plasma HIV-1 RNA Viral Loads and Is Not Enhanced by Sexually Transmitted Bacterial Infections of the RectumThe Journal of Infectious Diseases, 2011
- Prevention of HIV-1 Infection with Early Antiretroviral TherapyThe New England Journal of Medicine, 2011
- Single and Multiple Dose Pharmacokinetics of Maraviroc in Saliva, Semen, and Rectal Tissue of Healthy HIV-Negative MenThe Journal of Infectious Diseases, 2011
- Differences in HIV Burden and Immune Activation within the Gut of HIV‐Positive Patients Receiving Suppressive Antiretroviral TherapyThe Journal of Infectious Diseases, 2010
- Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based studyThe Lancet, 2010
- Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysisThe Lancet, 2010
- Rethinking the heterosexual infectivity of HIV-1: a systematic review and meta-analysisThe Lancet Infectious Diseases, 2008
- Setting the stage: host invasion by HIVNature Reviews Immunology, 2008
- Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infectionProceedings of the National Academy of Sciences of the United States of America, 2008
- The Use of Rectal Douches among HIV-uninfected and Infected Men who Have Unprotected Receptive Anal Intercourse: Implications for Rectal MicrobicidesAIDS and Behavior, 2007